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Abstract
Lacosamide has been submitted for regulatory approval in the United States and Europe for the
treatment of epilepsy. Previous synthetic methods did not permit the elaboration of the structure–
activity relationship (SAR) for the 3-oxy site in lacosamide. We report an expedient five-step
stereospecific synthesis for N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide analogs
beginning with D-serine methyl ester. The procedure incorporated alkyl (e.g. methyl, primary,
secondary, and tertiary) and aryl groups at this position. The SAR for the 3-oxy site showed maximal
activity in animal seizure models for small 3-alkoxy substituents.
Keywords
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1. Introduction
Lacosamide (Vimpat®, (R)-1) is an emerging neurological agent that has shown therapeutic
efficacy for the treatment of partial seizures. It has been submitted for regulatory approval in
the United States and Europe under the sponsorship of UCB Pharma.1,2 Evaluation of 1 in
animal seizure models at the National Institutes of Neurological Disorders and Stroke's
(NINDS) Anticonvulsant Screening Program (ASP) showed that it exhibited potent
anticonvulsant activity in the maximal electroshock seizure (MES) test in mice (ip) and rats
(po).3
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In 1996, we reported an expeditious three-step synthesis of (R)-1 from D-serine (Scheme 1).3
The 3-methoxy unit was installed by a Williamson-type ether synthesis using MeI and Ag2O.
Using race-mic 4 and either EtI or allyl iodide in place of MeI gave the corresponding O-
substituted derivatives 5 and 6, respectively.3 Efforts to extend the synthesis to other O-
substituted analogs led to appreciably lower yields of the desired ethers.4 This synthetic
impediment prevented our determining the structure–activity relationship (SAR) for the 3-oxy
substituent. We report herein an expedient stereospecific synthesis of (R)-N-benzyl-2-
acetamido-3-oxysubstituted propionamides (7) and document the importance of the 3-oxy
substituent for anticonvulsant activity within this novel class of agents.
2. Results and discussion
2.1. Synthesis
We sought a general and efficient procedure to prepare 7 that would permit different
substituents at the 3-oxy site. Okawa and coworkers demonstrated that N-Cbz-substituted
aziridines 8 underwent ring opening with alcohols and thiols using catalytic amounts of
BF3·Et2O to give the corresponding 3-substituted derivatives 9.5,6Similar procedures have
been used by Larsson and Carlson,7
and Zavada and coworkers.8 The synthetic utility of the Okawa procedure was hampered by
the time required by the five-step synthesis of 8 from the desired serine ester hydrochloride.
5 In 1989, van Boom reported a solution to this problem.9 Utilizing Evans’ one-step
cyclodehydration conversion of 2-amino alcohols to aziridines with
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diethoxytriphenylphosphorane (DTPP),10 treatment of 10 with DTPP provided the
unsubstituted (2S)-aziridine-2-carboxylates 11.
Thus, we treated D-serine methyl ester (12) with DTTP to give the desired methyl (2R)-
aziridine-2-carboxylate (13a) along with the corresponding ethyl ester 13b in 50−60% total
yield (Scheme 2). The production of the ethyl ester 13b was surprising. The amount of ethyl
ester varied with each reaction and appeared to increase with increasing reaction time, and
increasing amounts of DTPP.11 Since the ester group was hydrolyzed to the acid in a
subsequent step to permit amide coupling, we used the binary mixture of esters without
separation. With an expedient route to 13, we evaluated the generality of the BF3·Et2O
catalyzed alcohol ring-opening reaction for this set of aziridines. We restricted our studies to
the (R)-stereoisomer since we have shown that the pharmacological activity for this class of
substituted amino acids principally resided in the D-serine stereochemical series.3 Accordingly,
we converted 13a and 13b to methyl and ethyl (2R)-N-(acetyl)aziridine-2-carboxylates (14a
and 14b) in 94% yield with acetic anhydride, Et3N, and a catalytic amount of DMAP. Treatment
of 14a and 14b with MeOH, the primary alcohols, EtOH and diethylene glycol monomethyl
ether (DEGME), the secondary alcohol, iPrOH, the tertiary alcohol, tert-BuOH, and phenol
with one equivalent of BF3·Et2O gave the corresponding aziridine ring-opening products
(15a,b–20a,b) in 50−60% isolated yield. The alcohols produced little differences in yields.
Conversion of esters 15a,b–20a,b to the N-benzyl amides 1, 27−31, respectively, followed
established procedures. First, we hydrolyzed methyl (ethyl) esters 15−20 with stoichiometric
amounts of LiOH (1.0−1.1 equiv) at 0 °C to provide the free acids 21−26 upon workup. Under
these conditions we detected little or no racemization. Coupling acids 21−26 with benzylamine
and 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM)12
provided the amides 1, 27−31, respectively. After column purification and subsequent
recrystallization we saw that the spectral and analytical data for 1, 27−31 were in agreement
with their proposed structures. Adding the chiral resolving agent (R)-(−)-mandelic acid to a
CDCl3 solution of each amide showed only one signal for the acetamide methyl resonance
consistent with the expected enantiopurity of the products.3,13
2.2. Pharmacological activity
Compounds 1 and 27−31 were tested for anticonvulsant activity by the NIH and NINDS's
Anticonvulsant Screening Program (ASP) using the procedures described by Stables and
Kupferberg.14 The pharmacological data are summarized in Table 1, along with similar results
obtained for 1 and the established antiepileptic agents phenytoin, valproate, and phenobarbital.
We observed that the N-benzyl (2R)-3-alkoxysubstituted 2-acetamidopropionamides 1, 27, and
29−31 exhibited moderate-to-excellent anticonvulsant activity in the MES-seizure test in mice
(ip). Among the 3-alkoxy-substituted derivatives, activity improved with a coinciding decrease
of the 3-alkoxy group's size. Thus, the MES ED50 values declined from a range between 30
mg/kg and 100 mg/kg for the tert-butoxy analog 30, down to 23 mg/kg for 29, to 7.9 mg/kg
for 27 and finally to 4.5 mg/kg for the O-methoxy compound 1. The anticonvulsant activities
for 1 and 27 exceeded that of phenytoin.15 Paralleling this increase, we observed a neurological
toxicity increase in the rotorod test16 similar to earlier findings.3 Introduction of a 3-phenoxy
unit in place of the 3-methoxy group in 1 to give 31 led to a marked activity reduction in the
MES test (ED50 >100 mg/kg but still <300 mg/kg). Finally, the polyether 28 exhibited neither
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anticonvulsant nor neurological activity at the dose evaluated (up to 300 mg/kg). We
hypothesize that the loss of neurological activity is due to the inability of this hydrophilic
derivative to cross the blood brain barrier. No N-benzyl-3-oxysubstituted 2-
acetamidopropionamides 1 and 27−31 showed detectable activity in the pentylenetetrazole test
(scMet) in mice (data not shown), which is in agreement with similar test results observed for
this class of compounds.3
3. Conclusions
We have established a convenient, general, stereospecific synthetic method for the preparation
of N-benzyl-3-oxysubstituted 2-acetamidopropionamides (7). The route takes advantage of a
rapid and short synthesis of 14 using readily available DTPP.10 Key to the preparation of these
compounds is the BF3·Et2O ring opening of aziridine 14 with alcohols and phenol. Little
differences in the yields for ring opening were observed when we varied the size and
nucleophilicity of the alcohol or phenol.
4. Experimental
4.1. General methods
Melting points were determined with a Thomas-Hoover melting point apparatus and are
uncorrected. Infrared spectra (IR) were run on a ATI Mattson Genesis Series FTIR™
spectrometer. Absorption values are expressed in wave-numbers (cm−1). Optical rotations were
obtained on a Jasco P-1030 polarimeter. Proton (1H NMR, 300 MHz) and carbon (13C NMR,
75 MHz) nuclear magnetic resonance spectra were taken on a Varian Gemini 2000
spectrometer. The high-resolution mass spectrum was performed on a Bruker Apex-Q 12 Tesla
FTICR by Dr. M. Crowe at the University of North Carolina—Chapel Hill. Microanalysis was
provided by Atlantic Microlab, Inc. (Norcross, GA).
4.2. Synthesis of diethoxytriphenylphosphorane (DTPP)
Triphenylphosphine (110.00 g, 419 mmol) was dissolved in anhydrous toluene (500 mL) and
the solvent was evaporated. The solid was redissolved in a 1:1 mixture of anhydrous CH2Cl2
(350 mL) and THF (350 mL) and cooled at −78 °C (dry ice/acetone bath). While stirring,
Br2 (21.5 mL, 419 mmol) was added all at once with a syringe and the reaction was stirred at
−78 °C (10 min). Commercial NaOEt (96%, 59.35 g, 838 mmol) was added portionwise over
5 min, and then anhydrous EtOH (44 mL, 838 mmol) was added dropwise to the formed
suspension. The reaction was stirred at −78 °C (90 min), and allowed to warm to room
temperature. The supernatant was decanted and filtered over a Celite bed. The remaining
suspension was centrifuged at 1600 rpm for 15 min. The supernatant layers obtained from both
fractions were combined and evaporated at 30 °C. Hexanes (500 mL) were added to the oily
residue and the mixture was shaken for 5 min. The triphenylphosphine oxide (TPPO) was
filtered, and the solvent removed in vacuo. Additional hexanes (500 mL) were added to the
solid and the flask was let stand on ice for 20 min. Additional TPPO was filtered and the solvent
evaporated to yield DTPP as a white to pale yellow solid (66.42 g, 45% yield, 90% pure by
wt): 1H NMR (CDCl3) δ 0.75 (t, J = 7.0 Hz, P(OCH2CH3)2), 2.53 (app q, J = 7.0 Hz, P
(OCH2CH3)2), 7.39−7.47 (m, 9 ArH), 8.04−8.12 (m, 6 ArH); 13C NMR (CDCl3) 16.4 (d, J =
5.1 Hz, P(OCH2CH3)2), 57.5 (d, J = 6.8 Hz, P(OCH2CH3)2), 127.8, 129.4, 132.7 (15 ArC),
139.2 (d, J = 173.0 Hz, 3 ArC). The DTPP obtained under these conditions was 85−95% pure
by weight and was contaminated with TPPO (1H NMR analysis).
4.3. General procedure to generate D-serine methyl ester ((R)-12)
D-Serine methyl ester hydrochloride (1 equiv) was suspended in acetonitrile ([C] ∼ 1 M) and
Et3N (1.5 equiv) was added. After stirring at room temperature (1 h), the salts were filtered
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and rinsed with EtOAc and an equal volume of EtOAc was added. The mixture was stirred at
0 °C (10 min), the solids filtered, and then approximately two thirds of the solvent volume
removed in vacuo. The remaining reaction mixture was stirred at 0 °C (10 min), filtered, and
the solvent removed. The resulting oil was dissolved in acetonitrile and the solvent evaporated
to remove excess Et3N. The preceding step was repeated until Et3N could not be detected,
yielding the free amine of D-serine methyl ester as a pale yellow oil (∼90%) that solidified upon
standing overnight. (R)-12 was best used as an oil since solid (R)-12 did not readily dissolve
in organic solvents.
4.4. Synthesis of (R)-methyl N-acetylaziridine-carboxylate ((R)-14a) and (R)-ethyl N-
acetylaziridine-carboxylate ((R)-14b)
To a solution of D-serine methyl ester (41.30 g, 347 mmol) in acetonitrile (500 mL) was added
DTPP (86% by wt, 142.00 g, 346 mmol). The solution was stirred at room temperature (24 h).
The solvent was removed in vacuo, the residue dissolved in minimal amount of CH2Cl2 (250
mL), and extracted with aqueous 0.1 M H2SO4 until the pH of the aqueous phase remained
acidic (3× 150 mL). The combined aqueous layers were washed with EtOAc (3× 200 mL),
basified (pH ∼ 10) with solid Na2CO3, saturated with NaCl until the solution became cloudy,
and extracted with EtOAc (6× 200 mL). The combined organic layers were dried (Na2SO4)
and evaporated to give a crude yellow liquid. Bulb-to-bulb distillation of the liquid at 80 °C
under vacuum (6 mm Hg) yielded an approximately 9:1 molar mixture of (R)-13a and
(R)-13b as a colorless liquid (24.60 g, 69%). The mixture was directly dissolved in CH2Cl2
(500 mL) and Et3 N (33.4 mL, 239 mmol) and DMAP (1.46 g, 12 mmol) were successively
added. While stirring at room temperature (water bath), Ac2O (22.6 mL, 239 mmol) was added
dropwise over 15 min and the reaction was then allowed to proceed at room temperature (45
min). The reaction was successively washed with a 10% aqueous citric acid solution (500 mL),
and brine (500 mL), dried (Na2SO4), and the solvents were removed in vacuo to yield an
approximately 9:1 molar mixture of a colorless residue (32.80 g, 94%) that was used without
further purification: Rf = 0.38 ((R)-14a), 0.39 ((R)-14b) (2:1 hexanes/EtOAc). Spectral data
for (R)-14a (∼90 mol percent based on 1H NMR integrations): 1H NMR (CDCl3) δ 2.16 (s,
CH3C(O)), 2.49 (dd, J = 1.8, 7.0 Hz, NCHH′CH), 2.58 (dd, J = 3.0, 7.0 Hz, CHCOOCH3),
3.15 (dd, J = 1.8, 3.0 Hz, NCHH′CH), 3.80 (s, CO2CH3); 13C NMR (CDCl3) δ 23.8 (CH3C
(O)), 31.0 (NCH2CH), 34.5 (CHCO2CH3), 52.9 (CO2CH3), 168.9 (CH3C(O)), 180.6
(COOCH3); (R)-14a was not detected by HRMS.
Spectral data for (R)-14b (∼10 mol percent based on 1H NMR integrations): 1H NMR
(CDCl3) δ 1.31 (t, J = 6.9 Hz, C(O)OCH2CH3), 4.24 (q, J = 6.9 Hz, C(O)OCHH′CH3), 4.25
(q, J = 6.9 Hz, C(O)OCHH′CH3), the remaining signals were not detected and are believed to
overlap with the 1H signals for (R)-14a; 13C NMR (CDCl ) no 13C signals were detected for
(R)-14b; Mr (+ESI) [M+Na]+ (calcd for C7H11NO3Na+ 180.0637) 180.0631.
4.5. General procedure for the aziridine ring opening of (R)-14a/(R)-14b with alcohols. Method
A
To a cooled solution (ice bath) of a binary mixture of (R)-14a and (R)-14b in the appropriate
alcohol or in CH2Cl2 ([C] ∼ 0.5−1 M) was added BF3·Et2O (1 equiv) dropwise while stirring.
Upon addition, the mixture was warmed to room temperature and stirred for an additional 90
min. An equal volume of saturated aqueous NaHCO3 was added to the solution and after 15
min of vigorous stirring, the organic layer separated. The aqueous layer was extracted with
CH2Cl2 until no more product was detected (TLC analysis). The combined organic layers were
combined, dried (Na2SO4), and removed in vacuo to yield a mixture of methyl and ethyl esters
that was either used without further purification or, when needed, purified by flash column
chromatography.
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4.6. General procedure for the methyl/ethyl ester hydrolysis of (R)-15a/(R)-15b-(R)-20a/
(R)-20b with LiOH. Method B
To a solution of methyl and ethyl esters in 2 volumes of THF ([C] ∼ 0.1 M) was added LiOH
(1 equiv) in 1 volume of H2O. The reaction was stirred at room temperature (90 min), after
which time the aqueous layer was washed with Et2O (2 volumes). The aqueous layer was
acidified (pH 1) by the dropwise addition of aqueous concentrated HCl at 0 °C, saturated with
NaCl, and extracted with EtOAc until no further product was detected (TLC analysis). The
combined organic layers were combined, dried (Na2SO4), and evaporated to an oily residue
that was used directly in the next step, or recrystallized when needed from EtOAc and hexanes
to provide an analytical sample.
4.7. General procedure for the DMTMM amide coupling reaction. Method C
To a THF solution of acid ([C] ∼ 0.1 M) at room temperature was added benzylamine (1.2
equiv). The solution was stirred for 5−10 min until the benzylammonium carboxylate
precipitated. While stirring, DMTMM (1.2 equiv) was added at once, and the resulting
suspension was stirred at room temperature (3−12 h). In those cases where a salt did not
precipitate, DMTMM was added after 15 min to the solution. The salts were removed by
filtration, washed with THF, and the solvent was removed in vacuo. The obtained residue was
purified by flash column chromatography to afford the benzylamide, and then recrystallized
with EtOAc and hexanes.
4.8. Synthesis of (R)-methyl 2-acetamido-3-methoxypropionate ((R)-15a) and (R)-ethyl 2-
acetamido-3-methoxypropionate ((R)-15b)
Using Method A, a ∼ 9:1 mixture of (R)-14a and (R)-14b (5.46 g, 40.6 mmol), and BF3·Et2O
(5.1 mL, 40.6 mmol) in MeOH (50 mL) gave 3.95 g (56%) of (R)-15a and (R)-15b as a pale
yellow residue that solidified under high vacuum and was used without further purification:
Rf = 0.40 ((R)-15a), 0.42 ((R)-15b) (5:95 hexanes/EtOAc); IR (CH2Cl2 film) 3300, 3062, 2996,
2940, 1743, 1656, 1547, 1444, 1380, 1214, 1119 cm−1. Spectral data for (R)-15a (∼90 mol
percent based on 1H NMR integrations): 1H NMR (CDCl3) δ 2.06 (s, CH3C(O)NH), 3.34 (s,
OCH3), 3.61 (dd, J = 4.0, 9.3 Hz, CHCHH′OCH3), 3.77 (s, C(O)OCH3), 3.81 (dd, J = 4.0, 9.3
Hz, CHCHH′OCH3), 4.75 (app dt, J = 4.0, 7.8 Hz, CHCH2OCH3), 6.74 (br d, J = 7.8 Hz,
CH3C(O)NH); 13C NMR (CDCl3) δ 22.9 (CH3C(O)), 52.4 (CHCH2OCH3 or C(O)OCH3),
52.5 (C(O)OCH3 or CHCH2OCH3), 59.1 (CH2OCH3), 72.2 (CHCH2OCH3), 170.1, 170.8
(CH3C(O)NH, C(O)OCH3); Mr (+ESI) [M+Na]+ (calcd for C7H13NO4Na+ 198.0742)
198.0740.
Spectral data for (R)-15b (∼10 mol percent based on 1 HNMR integrations): 1H NMR
(CDCl3) δ 1.29 (t, J = 7.2 Hz, C(O)OCH2CH3) 1.99 (s, CH3C(O)NH), 3.44 (s, OCH3), 3.92
(dd, J = 4.0, 9.3 Hz, CHCHH′OCH3), 4.19−4.28 (m, C(O)OCH2CH3), 6.40−6.50 (br d,
CH3C(O)NH), the remaining peaks were not detected and are believed to overlap with
(R)-15a signals; 13C NMR signals were not detected for (R)-15b; Mr (+ESI) 212.0896 [M
+Na]+ (calcd for C8H15NO4Na+ 212.0899 [M+Na]+).
4.9. Synthesis of (R)-methyl 2-acetamido-3-ethoxypropionate ((R)-16a) and (R)-ethyl 2-
acetamido-3-ethoxypropionate ((R)-16b)
Using Method A, a mixture of (R)-14a and (R)-14b (∼90% (R)-14a and ∼10% (R)-14b) (1.88
g, 13.0 mmol), and BF3·Et2O (1.63 mL, 13.0 mmol) in EtOH (25 mL) gave 1.34 g (54%) of
(R)-16a and (R)-16b as a pale yellow oil that was used without further purification: Rf = 0.43
((R)-16a), 0.45 ((R)-16b) (5:95 hexanes/EtOAc); IR (neat) 3287, 3064, 2977, 2876, 1745,
1661, 1542, 1442, 1375, 1212, 1119 cm−1. Spectral data for (R)-16a (∼90 mol percent based
on 1H NMR integrations): 1H NMR (CDCl3) δ 1.16 (t, J = 7.2 Hz, CH2OCH2CH3), 2.06 (s,
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CH3C(O)NH), 3.50 (q, J = 7.2 Hz, CH2OCHH′CH3), 3.51 (q, J = 7.2 Hz, CH2OCHH′CH3),
3.65 (dd, J = 4.0, 8.7 Hz, CHCHH′OCH2CH3), 3.76 (s, C(O)OCH3), 3.84 (dd, J = 4.0, 8.7 Hz,
CHCHH′OCH2CH3), 4.75 (app dt, J = 4.0, 7.5 Hz, CHCH2OCH2CH3), 6.54 (br d, J = 7.5 Hz,
CH3C(O)NH); 13C NMR (CDCl3) δ 15.0 (OCH2CH3), 23.3 (CH3C(O)), 52.7
(CHCH2OCH3 or C(O)OCH3), 52.8 (C(O)OCH3 or CHCH2OCH2H3), 67.1
(CHCH2OCH2CH3), 70.2 (CHCH2OCH2CH3), 170.1, 171.1 (CH3C(O)NH, C(O)OCH3); Mr
(+ESI) 212.0897 [M+Na]+ (calcd for C8H15NO4Na+ 212.0899 [M+Na]+).
Spectral data for (R)-16b (∼10 mol percent based on 1 HNMR integrations): 1H NMR
(CDCl3) δ 1.24 (t, J = 7.2 Hz, CH2OCH2CH3 or C(O)OCH2CH3), 1.29 (t, J = 7.2 Hz, C(O)
OCH2CH3 or CH2OCH2CH3), 1.99 (s, CH3C(O)NH), 3.96−4.04 (m, CH2OCHH′CH3), 4.19
−4.30 (m, C(O)OCH2CH3), 6.10−6.22 (br d, J = 6.8 Hz, CH3C(O)NH), the remaining peaks
were not detected and are believed to overlap with (R)-16a signals; 13C NMR signals were not
detected for (R)-16b; Mr (+ESI) 226.1054 [M+Na]+ (calcd for C9H17NO4Na+ 226.1055 [M
+Na]+).
4.10. Synthesis of (R)-methyl 2-acetamido-3-(2-(2-methoxyethoxy)ethoxy)propionate
((R)-17a) and (R)-ethyl 2-acetamido-3-(2-(2-methoxyethoxy)ethoxy)propionate ((R)-17b)
Using Method A, a ∼1:1 mixture of (R)-14a and (R)-14b (4.50 g, 30.0 mmol), DEGME (11.3
g, 94.5 mmol), and BF3·Et2O (3.8 mL, 30.0 mmol) in CH2Cl2 (30 mL) gave 2.84 g (35%) of
(R)-17a and (R)-17b as a colorless viscous oil after purification by flash chromatography
column (2:1 hexanes/EtOAc to EtOAc): Rf = 0.31 ((R)-17a), 0.33 ((R)-17b) (EtOAc); IR (neat)
3300, 3063, 2940, 2940, 1744, 1659, 1553, 1446, 1216, 1120 cm−1. Spectral data for
(R)-17a and (R)-17b (1:1): 1H NMR (CDCl3) δ 1.28 ((R)-17b, t, J = 7.2 Hz, C(O)
OCH2CH3), 2.06 ((R)-17a,b, s, CH3C(O)NH), 3.39 ((R)-17a,b, s, CH2CH2OCH3), 3.52−3.58
((R)-17a,b, m, CH2CH2OCH3), 3.60−3.64 ((R)-17a,b, m, OCH2CH2OCH2), 3.68−3.74
((R)-17a,b, m, CHCHH′OCH2), 3.76 ((R)-17a, s, C(O)OCH3), 3.94, 3.97 ((R)-17a,b, app t,
J = 4.2 Hz CHCHH′OCH2), 4.22 ((R)-17b, t, J = 7.2 Hz, C(O)OCH2CH3), 4.68−4.76
((R)-17a,b, m, CHCH2OCH2), 6.52−6.70 ((R)-17a,b, m, CH3C(O)NH); 13C NMR (CDCl3)
δ 14.3 ((R)-17a,b, C(O)OCH2CH3), 23.1 ((R)-17a,b, CH3C(O)), 52.6, 52.9, 53.0 ((R)-17a,b,
CHCH2OCH2, (R)-17a, C(O)OCH3), 61.7 ((R)-17b, C(O)OCH2CH3), 70.5, 70.6, 71.1, 71.2,
71.3 ((R)-17a,b, OCH2-CH2OCH2CH2OCH3), 170.1, 170.4, 170.9 ((R)-17a,b, CH3C(O)NH,
C(O)OCH3), the remaining resonances were not detected and are believed to overlap with
nearby signals; Compound (R)-17a was not detected by HRMS; (R)-17b: Mr (+ESI) 300.1421
[M+Na]+ (calcd for C12H23NO6Na+ 300.1423 [M+Na]+).
4.11. Synthesis of (R)-methyl 2-acetamido-3-isopropoxypropionate ((R)-18a) and (R)-ethyl 2-
acetamido-3-isopropoxypropionate ((R)-18b)
Using Method A, a ∼9:1 mixture of (R)-14a and (R)-14b (3.40 g, 23.5 mmol), and BF3·Et2O
(2.95 mL, 23.5 mmol) in iPrOH (30 mL) gave 2.98 g (62%) of (R)-18a and (R)-18b as a pale
yellow oil: Rf = 0.46 ((R)-18a), 0.48 ((R)-18b) (5:95 hexanes/EtOAc); IR (neat) 3295, 3062,
2972, 2877, 1748, 1663, 1538, 1442, 1375, 1212, 1147 cm−1. Spectral data for (R)-18a (∼90
mol percent based on 1H NMR integrations): 1H NMR (CDCl3) δ 1.10 (d, J = 6.0 Hz,
CH2OCHCH3(C′H3)), 1.12 (d, J = 6.0 Hz, CH2OCHCH3(C′H3)), 2.06 (s, CH3C(O)NH), 3.55
(hept, J = 6.0 Hz, CH2OCH(CH3)2), 3.64 (dd, J = 3.7, 9.3 Hz, CHCHH′OCH(CH3)2), 3.76 (s,
C(O)OCH3), 3.84 (dd, J = 3.7, 9.3 Hz, CHCHH′OCH(CH3)2), 4.72 (app dt, J = 3.7, 7.2 Hz,
CHCH2OCH(CH3)2), 6.41 (br d, J = 7.2 Hz, CH3C(O)NH); 13C NMR (CDCl3) δ 21.5
(OCHCH3(C′H3)), 21.6 (OCHCH3(C′H3)), 22.9 (CH3C(O)), 52.1 (CHCH2OCH(CH3)2 or C
(O)OCH3), 52.6 (C(O)OCH3 or CHCH2OCH(CH3)2), 67.5 (CHCH2OCH(CH3)2), 70.2
(CHCH2OCH(CH3)2), 169.6, 170.4 (CH3C(O)NH, C(O)OCH3); Mr (+ESI) 226.1054 [M
+Na]+ (calcd for C9H17NO4Na+ 226.1055 [M+Na]+).
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Spectral data for (R)-18b (∼10 mol percent based on 1H NMR integrations): 1H NMR
(CDCl3) δ 1.16 (d, J = 6.0 Hz, CH2OCHCH3(C′H3)), 1.21 (d, J = 6.0 Hz, CH2OCHCH3(C′
H3)), 1.28 (t, J = 6.0 Hz, C(O)OCH2CH3), 1.99 (s, CH3C(O)NH), 4.06−4.12 (m, CHCHH′
OCH(CH3)2), 4.18−4.26 (m, C(O)OCH2CH3), 5.95−6.10 (br m, CH3C(O)NH), the remaining
signals were not detected and are believed to overlap with (R)-18a signals; 13C NMR signals
were not detected for (R)-18b; Mr (+ESI) 240.1211 [M+Na]+ (calcd for C10H19NO4Na+
240.1212 [M+Na]+).
4.12. Synthesis of (R)-methyl 2-acetamido-3-tert-butoxypropionate ((R)-19a) and (R)-ethyl 2-
acetamido-3-tert-butoxypropionate ((R)-19b)
Using Method A, a ∼9:1 mixture of (R)-14a and (R)-14b (3.50 g, 24.2 mmol), and BF3·Et2O
(3.05 mL, 24.2 mmol) in tert-BuOH (30 mL) gave 2.75 g (52%) of (R)-19a and (R)-19b as a
pale yellow oil: Rf = 0.52 ((R)-19a), 0.54 ((R)-19b) (5:95 hexanes/EtOAc); IR (neat) 3298,
3062, 2974, 1749, 1663, 1537, 1370, 1204, 1098 cm−1. Spectral data for (R)-19a (∼90 mol
percent based on 1H NMR integrations): 1H NMR (CDCl3) δ 1.14 (s, CH2OC(CH3)3), 2.06 (s,
CH3C(O)NH), 3.56 (dd, J = 3.0, 9.0 Hz, CHCHH′OC(CH3)3), 3.76 (s, C(O)OCH3), 3.81 (dd,
J = 3.0, 9.0 Hz, CHCHH′OC(CH3)3), 4.72 (app dt, J = 3.0, 7.2 Hz, CHCH2OC(CH3)3), 6.41
(br d, J = 7.2 Hz, CH3C(O)NH); 13C NMR (CDCl3) δ 22.9 (CH3C(O)), 27.7 (OC(CH3)3), 52.1
(CHCH2OC(CH3)3 or C(O)OCH3), 53.3 (C(O)OCH3 or CHCH2OCH(CH3)2), 62.4
(CHCH2OC(CH3)3), 73.8 (CHCH2OC(CH3)3), 170.3, 171.5 (CH3C(O)NH, C(O)OCH3); Mr
(+ESI) 240.1211 [M+Na]+ (calcd for C10H19NO4Na+ 240.1212 [M+Na]+).
Spectral data for (R)-19b (∼10 mol percent based on 1H NMR integrations): 1H NMR
(CDCl3) δ 1.21 (s, CH2OC(CH3)3), 1.99 (s, CH3C(O)NH), 4.18−4.24 (m, C(O)OCH2CH3),
5.95−6.15 (br m, CH3C(O)NH), the remaining signals were not detected and are believed to
overlap with (R)-19a signals or are too small to be detected; 13C NMR signals were not detected
for (R)-19b; Mr (+ESI) 254.1368 [M+Na]+ (calcd for C11H21NO4Na+ 254.1368 [M+Na]+).
4.13. Synthesis of (R)-methyl 2-acetamido-3-phenoxypropionate ((R)-20a) and (R)-ethyl 2-
acetamido-3-phenoxypropionate ((R)-20b)
Using Method A, a ∼3:7 mixture of (R)-14a and (R)-14b (2.00 g, 13.1 mmol), phenol (3.95 g,
42.0 mmol), and BF3·Et2O (1.6 mL, 13.1 mmol) in CH2Cl2 (20 mL) gave 1.40 g (43%) of
(R)-20a and (R)-20b as a slight yellow residue: Rf = 0.50 ((R)-20a), 0.52 ((R)-20b) (5:95
hexanes/EtOAc); IR (neat) 3067, 2984, 1743, 1660, 1596, 1541, 1498, 1379, 1296, 1238, 1159
cm−1; Spectral data for (R)-20a and (R)-20b (∼3:7): 1H NMR (CDCl3) δ 1.25 ((R)-20b, t, J =
7.2 Hz, C(O)OCH2CH3), 2.06 ((R)-20a,b, s, CH3C(O)NH), 3.76 ((R)-20a, s, C(O)OCH3), 4.20
−4.23 ((R)-20a,b, m, CHCHH′OPh), 4.24 ((R)-20b, q, J = 7.2 Hz, C(O)OCH2CH3), 4.36−4.43
((R)-20a,b, m, CHCHH′OPh), 4.68−5.06 ((R)-20a,b, m, CHCH2OPh), 6.52 ((R)-20a,b, d, J =
7.2 Hz, CH3C(O)NH), 6.84−6.90 ((R)-20a,b, m, 2 ArH (o)), 6.95−7.00 ((R)-20a,b, m, ArH
(p)), 7.24−7.32 ((R)-20a,b, m, 2 ArH (m)); 13C NMR (CDCl3) δ 14.3 ((R)-20b, C(O)
OCH2CH3), 23.1 ((R)-20a,b, CH3C(O)), 52.4, 52.5, 52.9 ((R)-20a,b, CHCH2OPh, (R)-20a, C
(O)OCH3), 62.1 ((R)-20b, C(O)OCH2CH3), 68.1, 68.2 ((R)-20a,b, CHCH2OPh), 114.8, 121.7,
129.7, 158.3, 158.4 ((R)-20a,b, CH2OPh), 170.0, 170.1, 170.5 ((R)-20a,b, CH3C(O)NH,
(R)-20a C(O)OCH3), the remaining signals were not detected and are believed to overlap with
nearby peaks; Compound (R)-20a, Mr (+ESI) 268.0895 [M+Na]+ (calcd for C12H15NO4Na+
260.0899 [M+Na]+); Compound (R)-20b, Mr (+ESI) [M+Na]+ (calcd for C12H15NO4Na+
274.1055 [M+Na]+) 274.1052.
4.14. Synthesis of (R)-2-acetamido-3-methoxypropionic acid ((R)-21)
Using Method B, a mixture of (R)-15a and (R)-15b (3.79 g, 21.5 mmol) in THF (210 mL), and
LiOH (515 mg, 21.5 mmol) in H2O (100 mL) gave 1.31 g (38%) of (R)-21 as a white solid
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after work-up and recrystallization from EtOAc: mp 108−109 °C;  −20.9° (c 0.65, MeOH)
(lit.17  −16.9° (c 1.2; MeOH)) for a partially racemized sample (∼4:1, (R)to (S))); Rf = 0
−0.1 (EtOAc); IR (nujol mull) 3352, 3100−2200, 1746, 1631, 1549, 1459, 1375 cm−1; 1H NMR
(DMSO-d6) δ 1.86 (s, CH3C(O)), 3.25 (s, CH2OCH3), 3.49 (dd, J = 3.9, 10.0 Hz, CHH′
OCH3), 3.63 (dd, J = 6.0, 10.0 Hz, CHH′OCH3), 4.36−4.45 (m, CHCH2O), 8.20 (d, J = 7.2
Hz, CH3C(O)NH), 12.7 (s, CO2H); 13C NMR (DMSO-d6) δ 22.3 (CH3C(O)), 52.1
(CHCH2OCH3), 58.3 (OCH3), 71.8 (CHCH2OCH3), 169.4, 171.7 (CHCO2H, CH3C(O)NH).
(R)-21 was not detected by HRMS. Anal. Calcd for C6H11NO4: C, 44.72; H, 6.88; N, 8.69.
Found: C, 44.75; H, 6.82; N, 8.77.
4.15. Synthesis of (R)-2-acetamido-3-ethoxypropionic acid ((R)-22)
Using Method B, a mixture of (R)-16a and (R)-16b (2.48 g, 13.0 mmol) in THF (130 mL), and
LiOH (312 mg, 13.0 mmol) in H2O (65 mL) gave 1.57 g (69%) of (R)-22 as a white solid after
work-up and recrystallization from EtOAc: mp 149−151 °C;  −31.5° (c 0.70, MeOH);
Rf = 0−0.15 (5:95 hexanes/EtOAc); IR (nujol mull) 3355, 3300−2100 (br), 1951, 1747, 1630,
1545, 1457, 1374, 1204, 1107 cm−1; 1H NMR (DMSO-d6) δ 1.09 (t, J = 6.9 Hz, OCH2CH3),
1.86 (s, CH3C(O)), 3.39−3.49 (m, CH2OCH2CH3), 3.53 (dd, J = 4.2, 10.0 Hz, CHH′
OCH2CH3), 3.63 (dd, J = 6.0, 10.0 Hz, CHH′OCH2CH3), 4.36−4.42 (m, CHCH2O), 8.15 (d,
J = 7.2 Hz, CH3C(O)NH), the carboxylic acid proton could not be detected; 13C NMR (DMSO-
d6) δ 14.9 (OCH2CH3), 22.3 (CH3C(O)), 52.4 (CHCH2OCH3), 65.8 (OCH2CH3), 69.6
(CHCH2OCH2CH3), 169.4, 171.7 (CHCO2H, CH3C(O)NH); Mr (+ESI) 214.0480 [M+K]+
(calcd for C7H13NO4K+ 214.0482 [M+K]+). Anal. Calcd for C7H13NO4: C, 47.99; H, 7.48;
N, 8.00. Found: C, 48.21; H, 7.56; N, 7.95.
4.16. Synthesis of (R)-2-acetamido-3-(2-(2-methoxyethoxy)ethoxy)propionic acid ((R)-23)
Using Method B, a mixture of (R)-17a and (R)-17b (3.85 g, 14.2 mmol) in THF (160 mL), and
LiOH (376 mg, 15.6 mmol) in H2O (80 mL) gave 2.44 g (68%) of (R)-23 as a colorless viscous
oil after work-up:  −38.5° (c 1.15, CHCl3); Rf = 0−0.11 (10:90 MeOH/CHCl3); IR (neat)
3500−2500 (br), 1974, 1731, 1654, 1547, 1103 cm−1; 1H NMR (CDCl3) δ 2.08 (s, CH3C(O)),
3.40 (s, OCH3), 3.54−3.70 (m, OCH2CH2OCH2CH2OCH3), 3.75 (dd, J = 3.3, 9.7 Hz, CHH′
OCH2), 3.98 (dd J = 3.3, 9.7 Hz, CHH′OCH2), 4.68−4.78 (m, CHCH2O), 6.98 (d, J = 7.8 Hz,
C(O)NHCH), 9.10−9.50 (br s, C(O)OH); 13C NMR (CDCl3) δ 22.9 (CH3C(O)), 53.0
(CHCH2OCH2CH2), 59.0 (OCH3), 70.3, 70.4, 70.7, 70.8, 72.1 (CH2OCH2CH2OCH2CH2O),
171.4, 172.3 (C(O)OH, CH3C(O)NH); Mr (+ESI) 272.1107 [M+Na]+ (calcd for
C18H20N2O3Na+ 272.1110 [M+Na]+). Anal. Calcd for C10H9NO6·0.33H2O: C, 46.50; H, 7.81;
N, 5.42. Found: C, 46.34; H, 7.74; N, 5.46.
4.17. Synthesis of (R)-2-acetamido-3-isopropoxypropionic acid ((R)-24)
Using Method B, a mixture of (R)-18a and (R)-18b (2.47 g, 12.0 mmol) in THF (120 mL), and
LiOH (288 mg, 12.0 mmol) in H2O (60 mL) gave 2.15 g (95%) of (R)-24 as a white solid after
work-up. Recrystallization from EtOAc and hexanes afforded an analytical sample: mp 128
−130 °C;  −36.5° (c 0.60, MeOH); Rf = 0.05−0.18 (5:95 hexanes/EtOAc); IR (nujol mull)
3366, 3300−2100 (br), 1751, 1636, 1548, 1457, 1376, 1328 cm−1; 1H NMR (DMSO-d6) δ 1.06
(d, J = 6.0 Hz, OCHCH3(C′H3)), 1.07 (d, J = 6.0 Hz, OCHCH3(C′H3), 1.87 (s, CH3C(O)), 3.49
−3.50 (m, CHH′OCH(CH3)2), 3.64 (dd, J = 5.7, 9.9 Hz, CHH′OCH(CH3)2), 4.33−4.40 (m,
CHCH2O), 8.10 (d, J = 7.2 Hz, CH3C(O)NH), 12.70 (CO2H); 13C NMR (DMSO-d6) δ 21.8
(OCHCH3(C′H3)), 21.9 (OCHCH3(C′H3), 22.4 (s, CH3C(O)), 52.6 (CHCH2OCH(CH3)2),
67.4 (CH2OCH(CH3)2), 71.3 (CH2OCH(CH3)2), 169.4, 171.8 (CH3C(O)NH, CO2H); Mr
(+ESI) 212.0897 [M+Na]+ (calcd for C8H15NO4Na+ 212.0899 [M+Na]+). Anal. Calcd for
C8H15NO4: C, 50.78; H, 7.99; N, 7.40. Found: C, 50.87; H, 8.02; N, 7.34.
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4.18. Synthesis of (R)-2-acetamido-3-tert-butoxypropionic acid ((R)-25)
Using Method B, a mixture of (R)-19a and (R)-19b (2.17 g, 9.90 mmol) in THF (100 mL), and
LiOH (237 mg, 9.90 mmol) in H2O (50 mL) gave 1.10 g (55%) of (R)-25 as a white solid after
work-up. Recrystallization from EtOAc and hexanes afforded an analytical sample: mp 154
−156 °C;  −46.7° (c 0.8, MeOH); Rf = 0.48 (5:95 hexanes/EtOAc); IR (nujol mull) 3370,
3300−2100 (br), 1875, 1708, 1613, 1542, 1459, 1371, 1229, 1103 cm−1; 1H NMR (DMSO-
d6) δ 1.11 (s, OC(CH3)3), 1.87 (s, CH3C(O)), 3.47 (dd, J = 4.2, 9.3 Hz, CHH′OC(CH3)3), 3.60
(dd, J = 5.1, 9.3 Hz, CHH′OC(CH3)3), 4.30−4.38 (m, CHCH2O), 8.01 (d, J = 7.2 Hz, CH3C
(O)NH), 12.6 (CO2H); 13C NMR (DMSO-d6) δ 22.4 (s, CH3C(O)), 27.2 (OC(CH3)3), 52.8
(CHCH2OC(CH3)3), 61.7 (CH2OC(CH3)3), 72.8 (CHCH2OC(CH3)3), 169.4, 171.9 (CH3C
(O)NH, CO2H); Mr (+ESI) 242.0794 [M+K]+ (calcd for C9H17NO4K+ 242.0795 [M+K]+).
Anal. Calcd for C9H17NO4: C, 53.19; H, 8.43; N, 6.89. Found: C, 53.04; H, 8.49; N, 6.84.
4.19. Synthesis of (R)-2-acetamido-3-phenoxypropionic acid ((R)-26)
Using Method B, a mixture of (R)-20a and (R)-20b (1.4 g, 5.7 mmol) in THF (60 mL), LiOH
(142 mg, 5.9 mmol) in H2O (30 mL) gave 950 mg (74%) of (R)-26 after recrystallization: mp
168−169.5 °C;  −91.2° (c 0.5, MeOH); Rf = 0−0.15 (10:90 MeOH/CHCl3); IR (nujol mull)
3362, 2300−2800 (br), 1950, 1746, 1607, 1551, 1461 cm−1; 1H NMR (DMSO-d6) δ 1.90 (s,
CH3C(O)), 4.13 (dd, J = 3.9, 9.6 Hz, CHH′OPh), 4.37 (dd J = 5.1, 9.6 Hz, CHH′OPh), 4.60
−4.68 (m, CHCH2O), 6.88−6.98 (m, OC6H5, (o) and (p)), 7.24−7.32 (m, OC6H5, (m)), 8.42
(d, J = 7.5 Hz, NHCHCH2), 12.50−13.00 (br, C(O)OH); 13C NMR (DMSO-d6) δ 22.3
(CH3C(O)), 51.8 (CHCH2OPh), 67.6 (CH2OPh), 114.6 (OC6H5, (o)), 121.0 (OC6H5,(p)),
129.8 (OC6H5, (m)), 158.1 (OC6H5, (i)), 169.5, 171.3 (CH3C(O)NH, CH3C(O)OH); Mr (+ESI)
246.0739 [M+Na]+ (calcd for C11H13NO4Na+ 246.0742 [M+Na]+). Anal. Calcd for
C11H13NO4·0.25H2O: C, 58.02; H, 5.98; N, 6.15. Found: C, 58.00; H, 5.98; N, 5.91.
4.20. Synthesis of (R)-2-acetamido-N-benzyl-3-methoxypropionamide ((R)-1)
Using Method C, (R)-21 (100 mg, 0.62 mmol), benzylamine (81 μL, 0.74 mmol), and DMTMM
(205 mg, 0.74 mmol) in anhydrous THF (10 mL) gave 95 mg (61%) of (R)-1 after flash column
chromatography (10:90 MeOH/CHCl3) and recrystallization from EtOAc: mp 142−143 °C (lit.
17 mp 142−143 °C);  +16.1° (c 0.9, MeOH) (lit.17  +16.0° (c 1.0; MeOH)); Rf = 0.47
(10:90 MeOH/CHCl3); 1H NMR (CDCl3) δ 2.03 (s, CH3C(O)), 3.37 (s, CH2OCH3), 3.46 (dd,
J = 7.2, 8.4 Hz, CHH′OCH3), 3.79 (dd J = 4.2, 8.4 Hz, CHH′OCH3), 4.40−4.52 (m,
NHCH2C6H5), 4.52−4.60 (m, CHCH2O), 6.40−6.60 (br m, CH3C(O)NH), 6.78−6.92 (br m,
C(O)NHCH2Ph), 7.18−7.38 (m, NHCH2C6H5), addition of excess (R)-(−)-mandelic acid to a
CDCl3 solution of (R)-1 gave only one signal for the acetyl methyl protons and the methoxy
protons, addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of authentic (S)-1 and
(R)-1 (1:2 ratio) gave two signals for the acetyl methyl protons (δ 2.023 (S) and 2.010 (R)
(Δppm = 0.013)), and two signals the methoxy protons (δ 3.311 (S) and 3.350 (R)(Δppm =
0.039)); 13C NMR (CDCl3) δ 23.4 (CH3C(O)), 43.7 (NHCH2Ph), 52.6 (CHCH2OCH3), 59.3
(CH2OCH3), 71.9 (CH2OCH3), 127.6, 127.7, 138.1 (NHCH2C6H5), 170.2, 170.5 (CHC(O)
NH, CH3C(O)NH), the remaining aromatic resonance was not detected and is believed to
overlap with nearby signals.
4.21. Synthesis of (R)-2-acetamido-N-benzyl-3-ethoxypropionamide ((R)-27)
Using Method C, (R)-22 (1.34 g, 7.7 mmol), benzylamine (1.00 mL, 9.2 mmol), and DMTMM
(2.54 g, 9.2 mmol) in anhydrous THF (80 mL) gave 1.11 g (46%) of (R)-27 as a white solid
after flash column chromatography (8:92 MeOH/CHCl3) and two recrystallizations from
EtOAc: mp 129−130 °C;  −34.1° (c 0.64, CHCl3); Rf = 0.35 (5:95 MeOH/CHCl3); IR
(nujol mull) 3283, 1634, 1555, 1456, 1375, 1114 cm−1; 1H NMR (CDCl3) δ 1.15 (t, J = 7.2
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Hz, OCH2CH3), 2.04 (s, CH3C(O)), 3.44 (dd, J = 8.4, 9.3 Hz, CHH′OCH2CH3), 3.48−3.62
(m, OCH2CH3), 3.85 (dd J = 4.2, 9.3 Hz, CHH′OCH2CH3), 4.40−4.58 (m, CHCH2OCH2,
NHCH2C6H5), 6.40−6.50 (br d, CH3C(O)NH), 6.78−6.90 (br t, C(O)NHCH2Ph), 7.22−7.38
(m, NHCH2C6H5), addition of excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-27
gave only one signal for the acetyl methyl protons (δ 2.017); 13C NMR (CDCl3) δ 15.1
(OCH2CH3), 23.3 (CH3C(O)), 43.6 (NHCH2Ph), 52.7 (CHCH2OCH2CH3), 67.0
(CHCH2OCH2CH3), 69.9 (CHCH2OCH2CH3), 127.6, 127.7, 128.7, 138.1 (NHCH2C6H5),
170.3, 170.5 (CHC(O)NH, CH3C(O)NH); Mr (+ESI) 287.1374 [M+Na]+ (calcd for
C14H20N2O3Na+ 287.1372 [M+Na]+). Anal. Calcd for C14H20N2O3: C, 63.62; H, 7.63; N,
10.60. Found: C, 63.62; H, 7.56; N, 10.47.
4.22. Synthesis of (R)-2-acetamido-N-benzyl-3-(2-(2-methoxyethoxy)ethoxy)propionamide
((R)-28)
Using Method C, (R)-23 (1.67 g, 6.70 mmol), benzylamine (876 μL, 8.04 mmol), and DMTMM
(2.22 g, 8.04 mmol) in THF (70 mL) gave a residue that was purified twice by flash
chromatography (5:95 MeOH/CHCl3) to yield (R)-28 (1.20 g, 53%) as a yellow oil that
progressively turned to an amorphous solid after 3 d under high vacuum: mp 48−52 °C;
 +7.7° (c 1.18, MeOH); Rf = 0.51 (10:90 MeOH/CHCl3); IR (neat) 3313, 3072, 2921,
2358, 2245, 1657, 1538, 1103 cm−1; 1H NMR (CDCl3) δ 2.02 (s, CH3C(O)), 3.26 (s, OCH3),
3.39−3.80 (m, CHH′OCH2CH2OCH2CH2OCH3), 4.05 (dd, J = 3.9 Hz, 9.9 Hz, CHH′
OCH2CH2O), 4.48 (d, J = 6.0 Hz, NHCH2C6H5), 4.54−4.62 (m, CHCH2O), 6.77 (d, J = 6.0
Hz, NHCH2C6H5), 7.20−7.39 (m, C6H5), addition of excess (R)-(−)-mandelic acid to a
CDCl3 solution of (R)-28 gave only one signal for the acetyl peak protons; 13C NMR
(CDCl3) δ 23.4 (CH3C(O)), 43.7 (NH2CH2C6H5), 52.5 (CHCH2OCH2CH2), 59.0 (OCH3),
70.4, 70.5, 70.6, 71.9 (OCH2-CH2OCH2CH2O), 127.5, 127.7, 128.8, 137.8 (C6H5), 170.3,
170.4 (CHC(O)NH, CH3C(O)), the remaining signal was not detected and is believed to
overlap with nearby peaks; Mr (+ESI) 361.1743 [M+Na]+ (calcd for C17H26N2O5Na+
361.1739 [M+Na]+). Anal. Calcd for C17H26N2O5·0.33H2O: C, 58.77; H, 7.83; N, 8.06. Found:
C, 58.59; H, 7.88; N, 8.10.
4.23. Synthesis of (R)-2-acetamido-N-benzyl-3-isopropoxypropionamide ((R)-29)
Using Method C, (R)-24 (1.90 g, 10.0 mmol), benzylamine (1.31 mL, 12.0 mmol), and
DMTMM (3.32 g, 12.0 mmol) in anhydrous THF (100 mL) gave 2.01 g (72%) of (R)-29 as a
white solid after flash column chromatography (5:95 MeOH/CHCl3) and recrystallization from
EtOAc: mp 151−153 °C;  −23.4° (c 0.50, CHCl3); Rf = 0.37 (5:95 MeOH/CHCl3); IR
(nujol mull) 3280, 3098, 1642, 1555, 1458, 1377, 1298, 1258, 1147 cm−1; 1H NMR (CDCl3)
δ 1.09 (d, J = 6.0 Hz, OCHCH3(C′H3)), 1.13 (d, J = 6.0 Hz, OCHCH3(C′H3)), 2.04 (s, CH3C
(O)), 3.40 (app t, J = 8.7 Hz, CHH′OCH(CH3)2), 3.63 (hept, J = 6.0 Hz, OCH(CH3)2), 3.84
(dd J = 3.9, 8.7 Hz, CHH′OCH(CH3)2), 4.38−4.57 (m, CHCH2OCH, NHCH2C6H5), 6.42−6.50
(br d, CH3C(O)NH), 6.82−6.94 (br t, C(O)NHCH2Ph), 7.24−7.38 (m, NHCH2C6H5), addition
of excess (R)-(−)-mandelic acid to a CDCl3 solution of (R)-29 gave only one signal for the
acetyl methyl protons (δ 2.014); 13C NMR (CDCl3) δ 22.0 (OCHCH3(C′H3)), 22.2
(OCHCH3(C′H3)), 23.4 (CH3C(O)), 43.7 (NHCH2Ph), 52.9 (CHCH2OCH(CH3)2), 67.5
(CH2OCH(CH3)2), 72.7 (CH2OCH(CH3)2), 127.7, 128.8, 138.1 (NHCH2C6H5), 170.5 (CHC
(O)NH or CH3C(O)NH), the remaining aromatic signal was not detected and is believed to
overlap with nearby signals, the second C(O) peak was not observed; Mr (+ESI) 301.1530 [M
+Na]+ (calcd for C15H22N2O3Na+ 301.1528 [M+Na]+). Anal. Calcd for C15H22N2O3: C,
64.73; H, 7.97; N, 10.06. Found: C, 64.56; H, 8.00; N, 10.12.
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4.24. Synthesis of (R)-2-acetamido-N-benzyl-3-tert-butoxypropionamide ((R)-30)
Using Method C, (R)-25 (1.10 g, 5.4 mmol), benzylamine (0.71 mL, 6.5 mmol), and DMTMM
(1.80 g, 6.5 mmol) in anhydrous THF (50 mL) gave 730 mg (46%) of (R)-30 as a white solid
after flash column chromatography (5:95 MeOH/CHCl3) and recrystallization from EtOAc:
mp 126−127 °C;  −22.9° (c 0.85, CHCl3); Rf = 0.39 (5/95 MeOH/CHCl3); IR (nujol mull)
3280, 3091, 1641, 1550, 1459, 1372, 1246, 1194, 1090 cm−1; 1H NMR (CDCl3) δ 1.14 (s, OC
(CH3)3), 2.04 (s, CH3C(O)), 3.40 (app t, J = 8.5 Hz, CHH′OC(CH3)3), 3.84 (dd, J = 4.2, 8.5
Hz, CHH′OC(CH3)3), 4.38−4.57 (m, CHCH2O, NHCH2C6H5), 6.40−6.50 (br d, CH3C(O)
NH), 6.80−6.92 (br t, C(O)NHCH2Ph), 7.23−7.40 (m, NHCH2C6H5), addition of excess (R)-
(−)-mandelic acid to a CDCl3 solution of (R)-30 gave only one signal for the acetyl methyl
protons (δ 2.009) and the tert-butoxy methyl protons (δ 1.112); 13C NMR (CDCl3) δ 23.4
(CH3C(O)), 27.6 (OC(CH3)3), 43.8 (NHCH2Ph), 53.2 (CHCH2OC(CH3)3), 61.7 (CH2OC
(CH3)3), 74.5 (CH2OC(CH3)3), 127.7, 127.8, 128.8, 138.1 (NHCH2C6H5), 170.3, 170.5
(CHC(O)NH, CH3C(O)NH); Mr (+ESI) 315.1687 [M+Na]+ (calcd for C16H24N2O3Na+
315.1685 [M+Na]+). Anal. Calcd for C16H24N2O3: C, 65.73; H, 8.27; N, 9.58; Found: C, 65.64;
H, 8.08; N, 9.57.
4.25. Synthesis of (R)-2-acetamido-N-benzyl-3-phenoxypropionamide ((R)-31)
Using Method C, (R)-26 (376 mg, 1.68 mmol), benzylamine (219 μL, 2.02 mmol), and
DMTMM (557 mg, 2.02 mmol) in THF (20 mL) gave a residue that was purified by flash
column chromatography (5:95 MeOH/CHCl3) and further recrystallized from EtOAc to yield
(R)-31 (305 mg, 58%) as a white solid: mp 169−170 °C;  −18.0° (c 0.4, MeOH); Rf = 0.52
(5/95 MeOH/CHCl3); IR (nujol mull) 3288, 3073, 1687, 1551, 1458, 1375 cm−1; 1H NMR
(CDCl3) δ 2.03 (s, CH3C(O)), 4.05 (dd, J = 7.5, 9.6 Hz, CHH′OCH3), 4.37 (dd J = 4.2, 9.6 Hz,
CHH′OCH3), 4.40−4.56 (m, NHCH2C6H5), 4.78−4.86 (m, CHCH2O), 6.66 (d, J = 6.0 Hz,
CH3C(O)NH), 6.87 (d, J = 7.8 Hz, OC6H5 (o)), 6.98 (t, J = 7.8 Hz, OC6H5 (p)), 7.16−7.35 (m,
CH2C6H5 (m) and NHCH2C6H5), addition of excess (R)-(−)-mandelic acid to a CDCl3 solution
of (R)-31 gave only one signal for the acetyl peak protons; 13C NMR (CDCl3) δ 23.4 (CH3C
(O)), 43.9 (NH2CH2Ph), 52.6 (CHCH2OPh), 67.4 (CH2OPh), 114.8 (OC6H5, (o)), 121.9
(OC6H5, (p)), 127.7, 127.8, 128.9 (CH2C6H5), 129.8 (OC6H5, (m)), 137.8 (CH2C6H5), 157.9
(OC6H5, (i)), 169.5, 170.6 (CHC(O)NH, CH3C(O)); Mr (+ESI) 335.1366 [M+Na]+ (calcd for
C18H20N2O3Na+ 335.1372 [M+Na]+). Anal. Calcd for C18H20N2O3: C, 69.21; H, 6.45; N,
8.97; Found: C, 69.29; H, 6.52; N, 9.05.
4.26. Pharmacology
Compounds were screened under the auspices of the National Institutes of Health's
Anticonvulsant Screening Program. Experiments were performed in male rodents [albino
Carworth Farms No. 1 mice (intraperitoneal route, ip), albino Sprague–Dawley rats (oral route,
po)]. Housing, handling, and feeding were in accordance with recommendations contained in
the ‘Guide for the Care and Use of Laboratory Animals’. Anticonvulsant activity was
established using the MES test14,18 and the scMet test,14 using previously reported methods.
19,20
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Three-step synthesis of (R)-lacosamide (1).
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Synthesis of N-benzyl-(2R)-2-acetamido-3-oxysubstituted propionamide derivatives.
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Table 1
Pharmacological data for N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamides derivatives




(R)-1e CH3 4.5 [0.5] (3.7−5.5) 27 [0.25] (26−28) 6
(R)-27 CH2CH3 7.9 [0.25] (5.3−10.4) 44 [0.25] (37−54) 5.6
(R)-28 CH2CH2OCH2CH2OCH3 >300 [0.5] >300 [0.5] –
(R)-29 CH(CH3)2 23 [0.25] (20−26) 77 [0.25] (66−96) 3.3
(R)-30 C(CH3)3 >30, <100 [0.5] >100, <300 [0.5] –
(R)-31 C6H5 >100, <300 [0.5] >30, <100 [0.5] –
Phenytoinf – 9.5 [2] (8.1−10) 56 [2] (53−72) 6.9
Phenobarbitalf – 22 [1] (15−23) 69 [0.5] (63−73) 3.2
Valproatef – 270 [0.25] (250−340) 430 [0.25] (370−450) 1.6
a
The compounds were administered intraperitoneally.
b
MES = maximal electroshock seizure test in mg/kg. Numbers in parentheses are 95% confidence intervals. The dose effect data was obtained at the ‘time
of peak’ effect (indicated in hours in the brackets).
c
Tox = neurologic toxicity determined from rotorod test in mice. Numbers in parentheses are 95% confidence intervals. The dose effect data was obtained
at the ‘time of peak’ effect (indicated in hours in the brackets).
d
PI = protective index (TD50/ED50).
e
Ref. 3.
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f
Refs. 15 and 18.
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